Fig. 1
From: KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors
KMT2A/C mutations predicted improved clinical outcomes in patients receiving ICI treatment. a The primary ICI-treated cohort (n = 546) was divided into the mutant (Mut) group and the wildtype (Wt) group according to the mutation status of individual KMT2 genes and KMT2A/C genes, then the difference of progression-free survival (PFS) between the two groups was compared. b Histogram demonstrating the proportions of patients achieving objective response (ORR, left panel) and durable clinical benefit (DCB, right panel) in the KMT2A/C-Mut and the KMT2A/C-Wt groups. c Kaplan-Meier curves of overall survival (OS) according to KMT2A/C mutation status in the ICI-treated cohort (n = 517 due to the lacking of OS information of 29 patients). Median OS and 2-year OS were also depicted